Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gallium Ga 68-NOTA-3PTATE-RGD

A radiopharmaceutical agent composed of a modified form of the somatostatin analogue octreotate (TATE), linked, via a glutamate linker, to the cyclic tri-amino acid arginine-glycine-aspartic acid (RGD) motif (3PTATE-RGD), and labeled, via the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) with the radioisotope gallium Ga 68, with potential somatostatin receptor type 2 (SSTR2) and alphaVbeta3 (aVb3) integrin imaging activity upon positron emission topography (PET) or single photon emission computed tomography (SPECT). After intravenous administration, gallium Ga 68-NOTA-3PTATE-RGD simultaneously binds to SSTR, with its TATE moiety (with a preference for SSTR2), and to the integrin receptor aVb3 with its RGD moiety. Both SSTR2 and aVb3 are expressed on the membrane of certain tumor cells while minimally or not expressed on healthy, normal cells. Upon PET imaging, SSTR2- and aVb3 integrin-expressing tumor cells can be visualized and expression levels can be quantified. SSTR2 and aVb3 play key roles in tumor proliferation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:68Ga-NOTA-3PTATE-RGD
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search